Exact Sciences Corporation (EXAS): Price and Financial Metrics


Exact Sciences Corporation (EXAS): $53.83

3.97 (+7.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EXAS POWR Grades


  • EXAS scores best on the Value dimension, with a Value rank ahead of 59.7% of US stocks.
  • The strongest trend for EXAS is in Growth, which has been heading down over the past 179 days.
  • EXAS ranks lowest in Growth; there it ranks in the 0th percentile.

EXAS Stock Summary

  • EXAS has a market capitalization of $12,515,501,064 -- more than approximately 83.35% of US stocks.
  • EXAS's price/sales ratio is 7.08; that's higher than the P/S ratio of 79.64% of US stocks.
  • With a year-over-year growth in debt of 37.5%, Exact Sciences Corp's debt growth rate surpasses 80.44% of about US stocks.
  • Stocks that are quantitatively similar to EXAS, based on their financial statements, market capitalization, and price volatility, are PAYC, SSTI, LMND, PHR, and ONTF.
  • Visit EXAS's SEC page to see the company's official filings. To visit the company's web site, go to www.exactsciences.com.

EXAS Valuation Summary

  • In comparison to the median Healthcare stock, EXAS's price/sales ratio is 7.49% lower, now standing at 10.5.
  • Over the past 243 months, EXAS's EV/EBIT ratio has gone down 9.2.
  • Over the past 243 months, EXAS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for EXAS.

Stock Date P/S P/B P/E EV/EBIT
EXAS 2021-08-31 10.5 5.0 -20.8 -19.0
EXAS 2021-08-30 10.4 5.0 -20.6 -18.8
EXAS 2021-08-27 10.4 5.0 -20.7 -18.9
EXAS 2021-08-26 10.2 4.9 -20.2 -18.5
EXAS 2021-08-25 10.2 4.9 -20.2 -18.5
EXAS 2021-08-24 10.0 4.8 -19.7 -18.1

EXAS Growth Metrics

    The year over year revenue growth rate now stands at 45.53%.
  • The 2 year cash and equivalents growth rate now stands at 371.47%.
  • The 3 year revenue growth rate now stands at 952.29%.
Over the past 52 months, EXAS's revenue has gone up $1,553,263,000.

The table below shows EXAS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,767.087 -102.236 -595.625
2021-09-30 1,759.614 33.74 -811.824
2021-06-30 1,711.598 156.289 -864.77
2021-03-31 1,545.647 109.082 -774
2020-12-31 1,491.391 136.482 -848.533
2020-09-30 1,320.627 -3.606 -333.778

EXAS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXAS has a Quality Grade of D, ranking ahead of 24.25% of graded US stocks.
  • EXAS's asset turnover comes in at 0.281 -- ranking 445th of 561 Business Services stocks.
  • ISGN, ADBE, and FTAI are the stocks whose asset turnover ratios are most correlated with EXAS.

The table below shows EXAS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.281 0.750 -0.310
2021-06-30 0.301 0.755 -0.344
2021-03-31 0.302 0.752 -0.332
2020-12-31 0.328 0.762 -0.274
2020-09-30 0.315 0.755 -0.171
2020-06-30 0.319 0.751 -0.126

EXAS Price Target

For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $148.88 Average Broker Recommendation 1.28 (Strong Buy)

EXAS Stock Price Chart Interactive Chart >

Price chart for EXAS

EXAS Price/Volume Stats

Current price $53.83 52-week high $133.99
Prev. close $49.86 52-week low $46.15
Day low $49.91 Volume 1,797,200
Day high $53.84 Avg. volume 2,125,790
50-day MA $61.04 Dividend yield N/A
200-day MA $79.77 Market Cap 9.47B

Exact Sciences Corporation (EXAS) Company Bio


Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.


EXAS Latest News Stream


Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream


Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

10 Stocks in Focus After Posting Their Earnings Reports

In this article, we will take a look at the 10 stocks in focus after posting their earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Stocks in Focus After Posting Their Earnings Reports. Recently, stocks from the consumer cyclical and healthcare sectors, including Lowe’s Companies, Inc. […]

Yahoo | February 24, 2022

Invest in Next-Gen Technologies With These 2 ETFs

As with many other instances of investing in uncertain waters, exchange-traded funds (ETFs) can come to the rescue of investors. Two particularly attractive funds for investors to consider today are the ARK Genomic Revolution ETF (NYSEMKT: ARKG) and the Global X Robotics & Artificial Intelligence ETF (NASDAQ: BOTZ). Companies in ARK Invest's Genomic Revolution ETF are ones that are working on extending and improving human life.

Yahoo | February 24, 2022

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q4 2021 Results - Earnings Call Transcript

Exact Sciences Corporation (EXAS) Q4 2021 Earnings Conference Call February 22, 2022 17:00 ET Company Participants Megan Jones - Senior Director, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Jeff Elliott - Chief Financial Officer and Chief Operating Officer Conference Call Participants Matt Sykes - Goldman Sachs Brandon...

SA Transcripts on Seeking Alpha | February 23, 2022

Exact Sciences Corporation 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Exact Sciences Corporation in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 23, 2022

Where Exact Sciences Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ: EXAS ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0 Last 30D 0 2 2 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Exact Sciences has an average price target of $95.0 with a high … Full story available on Benzinga.com

Benzinga | February 23, 2022

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo -6.43%
3-mo -31.27%
6-mo -37.82%
1-year -51.30%
3-year -44.91%
5-year 61.55%
YTD -30.84%
2021 -41.26%
2020 43.26%
2019 46.56%
2018 20.10%
2017 293.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7934 seconds.